1-8 of 8
Jason E. Hill
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

Clinical Trials & Observations
Mark J. Levis, Mehdi Hamadani, Brent R. Logan, Richard J. Jones, Anurag K Singh, Mark R Litzow, John R. Wingard, Esperanza B. Papadopoulos, Alexander E. Perl, Robert J. Soiffer, Celalettin Ustun, Masumi Ueda Oshima, Geoffrey L Uy, Edmund K. Waller, Sumithira Vasu, Melhem M Solh, Asmita Mishra, Lori Muffly, Hee-Je Kim, Matthias Stelljes, Yuho Najima, Masahiro Onozawa, Kirsty J Thomson, Arnon Nagler, Andrew H Wei, Guido Marcucci, Caroline Chen, Nahla Hasabou, Matt Rosales, Jason E. Hill, Stanley C. Gill, Rishita Nuthethi, Denise King, Adam M Mendizabal, Steven M. Devine, Mary M Horowitz, Yi-Bin Chen
Journal: Blood
Blood blood.2024025154.
https://doi.org/10.1182/blood.2024025154
Published: 2025
Includes: Supplemental data
Journal Articles

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Clinical Trials & Observations
Eunice S. Wang, Pau Montesinos, Mark D. Minden, Je-Hwan Lee, Michael Heuser, Tomoki Naoe, Wen-Chien Chou, Kamel Laribi, Jordi Esteve, Jessica K. Altman, Violaine Havelange, Anne-Marie Watson, Carlo Gambacorti-Passerini, Elzbieta Patkowska, Shufang Liu, Ruishan Wu, Nisha Philipose, Jason E. Hill, Stanley C. Gill, Elizabeth Shima Rich, Ramon V. Tiu
Journal: Blood
Blood (2022) 140 (17): 1845–1857.
https://doi.org/10.1182/blood.2021014586
Published: 2022
Includes: Supplemental data
Journal Articles

A Phase 1, Dose-Escalation Study of Gilteritinib Combined with Chemotherapy in Patients Aged 6 Months to <21 Years with FLT3 Internal Tandem Duplication-Positive Relapsed or Refractory AML

Philip Connor, Linyi Fan, Stanley Gill, Jason E. Hill, Nisha Philipose, David Delgado, Ramon V. Tiu, Dirk Reinhardt
Journal: Blood
Blood (2021) 138 (Supplement 1): 2315.
https://doi.org/10.1182/blood-2021-147862
Published: 2021
Journal Articles

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Eunice S. Wang, Pau Montesinos, Mark D. Minden, Je-Hwan Lee, Michael Heuser, Tomoki Naoe, Wen-Chien Chou, Kamel Laribi, Jordi Esteve, Jessica K. Altman, Violaine Havelange, Anne-Marie Watson, Elzbieta Patkowska, Shufang Liu, Ruishan Wu, Nisha Philipose, Jason E. Hill, Stanley Gill, Elizabeth Shima Rich, Ramon V. Tiu
Journal: Blood
Blood (2021) 138 (Supplement 1): 700.
https://doi.org/10.1182/blood-2021-145379
Published: 2021
Journal Articles

Impact of FLT3 Mutation Clearance after Front-Line Treatment with Gilteritinib Plus Azacitidine, or Gilteritinib or Azacitidine Alone in Patients with Newly Diagnosed AML: Results from the Phase 2/3 Lacewing Trial

Eunice S. Wang, Jessica K. Altman, Mark D. Minden, Ruishan Wu, Elizabeth Shima Rich, Jason E. Hill
Journal: Blood
Blood (2021) 138 (Supplement 1): 3445.
https://doi.org/10.1182/blood-2021-145362
Published: 2021
Journal Articles

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Keith W. Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS, Ramon V. Tiu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-137685
Published: 2020
Journal Articles

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Catherine C. Smith, MD, Mark J. Levis, MD, Alexander E. Perl, MD, Giovanni Martinelli, MD, Andreas Neubauer, MD, Ellin Berman, MD, Pau Montesinos, MD PhD, Maria R. Baer, MD, Richard A. Larson, MD, Wen-Chien Chou, MD, PhD, Hisayuki Yokoyama, MD PhD, Christian Recher, MD PhD, Sung-Soo Yoon, MD PhD, Jason E. Hill, Matt Rosales, Erkut Bahceci
Journal: Blood
Blood (2019) 134 (Supplement_1): 14.
https://doi.org/10.1182/blood-2019-122620
Published: 2019
Journal Articles

Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations

Mark J. Levis, MD, Alexander E. Perl, MD, Jessica K. Altman, MD, Jorge E. Cortes, MD, Catherine C. Smith, MD, Maria R. Baer, MD, David F. Claxton, MD, Joseph G. Jurcic, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Raoul Tibes, MD PhD, Jason E. Hill, PhD, Matt Rosales, Erkut Bahceci, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1458.
https://doi.org/10.1182/blood-2018-99-110971
Published: 2018